Western blot (WB) results revealed a significant increase in the expression of Ki-67 and Lamin B, while the protein levels of P21, P16, and -H2AX decreased following FOXO4-DRI treatment (Figure 4A)
If the effects are more acute, intermittent dosing might be sufficient
AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176-191 of human growth hormone, studied for its involvement in lipolysis, lipogenesis inhibition, and metabolic signalling pathways
FDA's Official Reasons: Lack of Clinical Trials: The FDA emphasizes the need for extensive, controlled clinical trials, which are currently lacking
Nothing in the published data licenses treating this molecule as a finished, approved medicine
These results prompted the spread of oral administration in Sweden and Canada [3]